Eav Lim, DO
Gynecologic Oncology · York, PANPI 1952694747
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,134 of the $4,303 with a category attached, or 72.8%. Intuitive Surgical accounts for 60.4% of it on its own, with 14 other manufacturers making up the rest.
Across 39 payments — averaging $110.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Eisai Inc.$337
- GSK$267
- Merck$247
- Baxter Healthcare$113
- Astellas Pharma US Inc$103
- plus $636 from 9 others
Across 3 payments — averaging $8128.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$17K
- Davol Inc.$7K
What the payments were for
- Travel & lodging$1,14827%
- Food & beverage$3,13473%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $2,601 |
| Eisai Inc. | 4 | $337 |
| GSK | 4 | $267 |
| Merck | 4 | $247 |
| Baxter Healthcare | 1 | $113 |
| Astellas Pharma US Inc | 1 | $103 |
| Genmab U.S., Inc. | 1 | $101 |
| AstraZeneca | 3 | $98 |
| Johnson & Johnson | 1 | $91 |
| Caris MPI, Inc. | 1 | $90 |
| Urocure LLC | 1 | $89 |
| Sanara Medtech Inc. | 1 | $81 |
| Clovis Oncology, Inc. | 1 | $56 |
| Smith+Nephew | 1 | $17 |
| Conmed Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,303 in reported general payments places this provider in the 75th percentile of 90 gynecologic oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 11 | $1,327 |
| Neomycin Sulfate | 78 | $344 |
| Ondansetron Hcl | 49 | $182 |
| Metronidazole | 83 | $180 |
| Oxycodone Hcl | 49 | $167 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in York
- Ali MahdaviYork$4K
- Gregory WillisYork$1K
- Thomas KrivakPittsburgh$1.6M
- Mark ShahinHershey$914K
- Joshua KestersonNewport$839K
- Charles DuntonWynnewood$309K
- M ThomasAllentown$257K
- Alexander OlawaiyePittsburgh$226K
- John NakayamaPittsburgh$194K
- Emily KoPhiladelphia$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.